<DOC>
	<DOCNO>NCT02361489</DOCNO>
	<brief_summary>The aim study observe patient Type 2 Diabetes basal insulin alone basal insulin oral agent efficiently safely start meal time insulin use U100 rapid act insulin analog V-Go® Disposable Insulin Delivery Device ( V-Go ) use one two dose titration algorithm achieve improve A1C 4 month .</brief_summary>
	<brief_title>Clinical Study Compare Various Dosing Titration Guidelines Insulin Delivered Via V-Go ® Patients With Type 2 Diabetes Initiating Basal Bolus Therapy Primary Care Offices</brief_title>
	<detailed_description>This study address informational need Primary Care Physicians regard provide insulin dose titration information utilize V-Go disposable insulin delivery device . We look compare two treatment arm insulin dose titration patient Type 2 insulin-dependent diabetes - fix dose titration arm , arm 50 % insulin dose give large meal day . This study provide practical information glycemic control , dose requirement safety patient Type 2 diabetes basal insulin without oral anti-diabetic agent primarily manage primary care office .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment study : Age ≥ 21 ≤80 time study enrollment Ability read understand English BMI ≥ 25 kg/m2 Weight le equal 300 pound . A1C ≥8 ≤12 % ( recent value within 4 week baseline visit ) Currently use basal insulin therapy ( NPH , Levemir , Lantus ) total daily dose 30 120 unit , basal dose great patient 's BMI # Willing attend physician 's office followup visit Willing able understand sign write informed consent form ( ICF ) indicate agree participate inform pertinent aspect study Must willing take record least 3 glucose measurement per time period ( prebreakfast , lunch , dinner bed ) per week . Willing optin Valeritas Customer Care receive device support reminder throughout study Most recent primary care office visit one participating site . Patients present follow exclusion criterion eligible enrollment study : Patient confirm Type 1 diabetes and/or patient weight great 300 lb . Diagnosis Autoimmune disease affect metabolism Currently use GLP1 medication Current ( within last 6 month ) plan use insulin pump diabetes management use U500 insulin . Ongoing participation clinical study Pregnant , lactate intend become pregnant Current chronic systemic steroid use Prior VGo use</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>